Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. insiders are currently net buyers of ELYM stock, showing bullish sentiment over the past 90 days. Executives have purchased $50.0M while selling $3.5M, resulting in a positive net flow of $46.5M. This buying activity represents 94% of total transaction volume.

Eliem Therapeutics, Inc. has 13 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Nexus Fund Ii, L.p. Ra (Executive) leads with 6 transactions totaling $40.0M. Industries Holdings Llc Access (Executive) follows with 2 transactions worth $10.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Eliem Therapeutics, Inc.'s current score of 94/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $50.0M in purchases versus $3.5M in sales.

The most recent insider transaction occurred on Sep 20, 2024, when Pimblett Emily (Executive) disposed of 1,182 shares at $8.18 per share for $9.7K. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, ELYM insider trading sentiment is currently bullish with an Alignment Score of 94/100. The net insider flow of $46.5M reflects accumulation, with 94% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Eliem Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ELYM, we track all Form 4 filings—currently showing 52 transactions from 13 insiders over 90 days.

A 10b5-1 plan allows Eliem Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ELYM, approximately 8% of recent transactions are 10b5-1 trades. The remaining 92% are discretionary trades, which may carry more informational value.

You can monitor Eliem Therapeutics, Inc. (ELYM) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 13 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Eliem Therapeutics, Inc.'s current score of 94/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $50.0M in purchases versus $3.5M in sales over 90 days, resulting in a net flow of $46.5M.

SEC Form 4 filings are mandatory reports that Eliem Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ELYM, the most common type is "S" with 17 occurrences. The most recent Form 4 was filed on Sep 20, 2024 by Pimblett Emily.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Eliem Therapeutics, Inc., approximately 8% of recent transactions are executed under 10b5-1 plans, while 92% appear to be discretionary trades. The low percentage means most insider activity at ELYM represents discretionary decisions with more informational value.